(firstQuint)Adalimumab for Inflammatory Osteoarthritis.

 This is a 20 patient pilot open-label study of the efficacy of adalimumab in inflammatory osteoarthritis of the knee.

 Primary endpoint is at 12 weeks and primary outcome is the OARSI responder index.

.

 Adalimumab for Inflammatory Osteoarthritis@highlight

We will conduct a pilot study of the effectiveness of adalimumab for inflammatory osteoarthritis.

